Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Salivary Gland Carcinoma

Salivary Gland Carcinoma

16

Pipeline Programs↗

7

Active Trials↗

10

Companies Involved↗

Salivary Gland Carcinoma is an emerging landscape with 16 programs across 10 companies.

Intelligence

Pipeline Metrics

Competitive Density

45/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

75/100

Attrition Rate

8/100

Pipeline

Programs by Phase

Preclinical1

Surufatinib

Hutchison Medipharma Limited

Phase 1

No programs

Phase 215

Abiraterone Combined With Dalpiciclib

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Darolutamide

Bayer

Pembrolizumab

Merck & Co.

Enfortumab Vedotin

Pfizer

Nivolumab

Bristol-Myers Squibb

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

67%

Small molecule

10 of 15 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 94% of 16 pipeline programs.

Analysis

Trial Status

12

clinical trials

Recruiting4 · 33%

Active, not recruiting3 · 25%

Completed3 · 25%

Unknown status1 · 8%

Withdrawn1 · 8%

Clinical Trials

Trial Activity

12 trials

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Recruiting·—·Phase 2·NCT04620187·55 enrolled

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Recruiting·PPeking Union Medical College·Phase 2·NCT06145308·39 enrolled

Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma

Recruiting·—·Phase 2·NCT05727410·50 enrolled

A Prospective, Open-Label, Single-Arm, Phase II Clinical Study of Abiraterone Combined With Dalpiciclib in Patients With HER-2-Negative, AR-Positive Recurrent/Metastatic Salivary Gland Carcinoma

Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT07815522·36 enrolled

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Active, not recruiting·FFudan University·Phase 2·NCT05924256·88 enrolled

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Active, not recruiting·National Cancer Center Hospital East·Phase 2·NCT05694819·56 enrolled

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Active, not recruiting·—·Phase 2·NCT03942653·20 enrolled

Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma

Completed·UUNICANCER·Phase 2·NCT02393820·72 enrolled

Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas

Completed·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT02776163·107 enrolled

Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck

Completed·UUNICANCER·Phase 2·NCT03132038·98 enrolled

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Withdrawn·AActuate Therapeutics Inc.·Phase 2·NCT04832438

Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas

Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·N/A·NCT05013515·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)